A new type of human interferon produced by peripheral blood mononuclear cells treated with inhibitors of transcription.
Peripheral blood mononuclear cells from human normal donors treated with inhibitors of transcription produce a protein with the properties of interferon (IFN) [activity against a broad range of viruses, species specificity, lack of blockade of virus attachment, capability to induce in cells durable antiviral state, establishment of antiviral state requiring ongoing protein and RNA synthesis, capability to induce 2',5'-oligoadenylate synthetase]. This IFN-like protein has a molecular weight of approximately 7000 daltons and is not neutralized by antibody to alpha-, beta-, and gamma-IFNs tested singularly or in a pooled fashion. Taken together the data suggest that this IFN-like protein may indeed be a new type of human IFN.
F
F
Dianzani
A
A
Dolei
P
P
Di Marco
D015088:2',5'-Oligoadenylate Synthetase / Q000378:metabolism; D002850:Chromatography, Gel; D003609:Dactinomycin / Q000494:pharmacology; D004004:Dichlororibofuranosylbenzimidazole / Q000494:pharmacology; D006801:Humans; D007371:Interferon-gamma / Q000032:analysis; D007372:Interferons / Q000032:analysis / Q000096:biosynthesis*; D008970:Molecular Weight; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism*; D009500:Neutralization Tests; D014176:Protein Biosynthesis; D014158:Transcription, Genetic / Q000187:drug effects*
D003609:Dactinomycin; D004004:Dichlororibofuranosylbenzimidazole; D007371:Interferon-gamma; D007372:Interferons; D015088:2',5'-Oligoadenylate Synthetase